or RSV. While they can receive passive protection from maternal antibodies or from prophylactic monoclonal antibodies given ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

Cold, dry air is the ideal climate for viruses like the flu, phenomena and Respiratory Syncytial Virus (RSV), and these low ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

Who should get vaccinated for RSV? This summer, the CDC altered its recommended guidance to 75 years for all seniors who have not yet been vaccinated. It still recommends that seniors 60 to 74 get ...

What if infections of respiratory syncytial virus, known as R.S.V., peak at unusual ... Flu season in America is no illusory concept, and I don’t mean to deride it, merely to expand it.

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Notably, quarterly sales of the company’s RSV vaccine, which became a blockbuster after debuting last year, fell by more than 70% year over year, in part due to narrower U.S. recommendations for ...

Influenza, RSV and SARS-CoV-2 are still the top three viruses to watch out for in the fall and winter, but several public health tools that have become available in the past year should help boost ...

The Centers for Disease Control and Prevention (CDC) recently warned that respiratory syncytial virus (RSV) and mycoplasma pneumonia, or “walking pneumonia,” are on the rise among very young ...

In years prior to the availability of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred annually among U.S. adults ...